J. Carpenter

929 total citations
23 papers, 720 citations indexed

About

J. Carpenter is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. Carpenter has authored 23 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in J. Carpenter's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (9 papers). J. Carpenter is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (9 papers). J. Carpenter collaborates with scholars based in United States, Italy and United Kingdom. J. Carpenter's co-authors include R. T. Chlebowski, Aman U. Buzdar, Paul P. Carbone, Matthew L. Baum, I. Craig Henderson, Kasper Langebjerg Andersen, Martin D. Abeloff, Rory Collins, O Abe and David L. Ahmann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Haematology.

In The Last Decade

J. Carpenter

23 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Carpenter United States	9	390	296	230	142	135	23	720
J.P. Lobelle Belgium	12	521 1.3×	343 1.2×	294 1.3×	134 0.9×	117 0.9×	25	794
Rosalin Cooper United Kingdom	10	499 1.3×	292 1.0×	221 1.0×	174 1.2×	104 0.8×	24	951
O Abe Japan	9	336 0.9×	270 0.9×	258 1.1×	120 0.8×	93 0.7×	45	736
WJ Gradishar United States	15	443 1.1×	211 0.7×	167 0.7×	175 1.2×	92 0.7×	48	718
S. Rubin Canada	10	562 1.4×	303 1.0×	188 0.8×	269 1.9×	247 1.8×	20	960
E Engelsman Netherlands	16	519 1.3×	359 1.2×	238 1.0×	112 0.8×	236 1.7×	37	940
D Perrault Canada	11	382 1.0×	162 0.5×	109 0.5×	56 0.4×	120 0.9×	16	610
Clarence B. Vaughn United States	15	349 0.9×	236 0.8×	80 0.3×	118 0.8×	128 0.9×	39	669
Ermelinda De Maio Italy	16	533 1.4×	284 1.0×	217 0.9×	425 3.0×	235 1.7×	30	1.1k
D. G. Kieback Germany	14	530 1.4×	393 1.3×	372 1.6×	221 1.6×	248 1.8×	31	946

Countries citing papers authored by J. Carpenter

Since Specialization

Citations

This map shows the geographic impact of J. Carpenter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Carpenter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Carpenter more than expected).

Fields of papers citing papers by J. Carpenter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Carpenter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Carpenter. The network helps show where J. Carpenter may publish in the future.

Co-authorship network of co-authors of J. Carpenter

This figure shows the co-authorship network connecting the top 25 collaborators of J. Carpenter. A scholar is included among the top collaborators of J. Carpenter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Carpenter. J. Carpenter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Anders, Carey K., Rachita Nanda, Kim T. Blackwell, et al.. (2011). TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM).. Journal of Clinical Oncology. 29(15_suppl). TPS127–TPS127. 3 indexed citations

Nabell, Lisle, J. Carpenter, CI Falkson, et al.. (2011). Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e11048–e11048. 1 indexed citations

Carpenter, J., et al.. (2010). Abstract P1-11-24: Concurrent and Sequential Bevacizumab and Preoperative Chemotherapy in the Treatment of Locally Advanced Breast Cancer: UAB 0493. Cancer Research. 70(24_Supplement). P1–11. 2 indexed citations

Li, Y., AF LoBuglio, Helen Krontiras, et al.. (2009). Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. Journal of Clinical Oncology. 27(15_suppl). e11566–e11566. 3 indexed citations

Falkson, Carla I., et al.. (2009). Update of a phase II trial of bevacizumab in combination with hormonal therapy to reverse acquired estrogen independence in metastatic breast cancer patients. Journal of Clinical Oncology. 27(15_suppl). e12027–e12027. 2 indexed citations

Forero, Andres, Mansoor N. Saleh, J. Galleshaw, et al.. (2009). A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer.. Cancer Research. 69(24_Supplement). 1088–1088. 2 indexed citations

Falkson, Carla I., Lisle Nabell, J. Carpenter, et al.. (2008). A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients. Journal of Clinical Oncology. 26(15_suppl). 1074–1074. 2 indexed citations

Forero‐Torres, Andres, J. Galleshaw, Caroline E. Jones, et al.. (2008). A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. Journal of Clinical Oncology. 26(15_suppl). 625–625. 8 indexed citations

Forero‐Torres, Andres, Ivor Percent, J. Galleshaw, et al.. (2007). A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report. Journal of Clinical Oncology. 25(18_suppl). 11020–11020. 2 indexed citations

10.

Krontiras, Helen, J. Carpenter, Lisle M. Nabell, et al.. (2006). Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. Journal of Clinical Oncology. 24(18_suppl). 10622–10622. 3 indexed citations

11.

Carpenter, J., H. Roché, Mario Campone, et al.. (2005). Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 564–564. 81 indexed citations

12.

Carpenter, J., et al.. (1986). Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.. PubMed. 70(9). 1073–9. 6 indexed citations

13.

Keller, Jacqui, A Bartolucci, J. Carpenter, & John R. Feagler. (1986). Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial.. PubMed. 70(10). 1221–3. 25 indexed citations

14.

Carpenter, J., et al.. (1986). Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.. PubMed. 70(10). 1235–6. 8 indexed citations

15.

Ettinger, David S., Joseph C. Allegra, Joseph R. Bertino, et al.. (1986). Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.. PubMed. 13(4 Suppl 4). 9–14. 35 indexed citations

16.

Carpenter, J., et al.. (1985). Use of megestrol acetate in advanced breast cancer on a single-daily-dose schedule.. PubMed. 12(1 Suppl 1). 40–2. 12 indexed citations

17.

Carpenter, J., et al.. (1982). Response to doxorubicin and mitomycin in cholangiocarcinoma: a case report.. PubMed. 66(1). 209–10. 4 indexed citations

18.

Carpenter, J., et al.. (1975). Breast cancer management: Part III. A comprehensive program for the management of breast cancer.. PubMed. 45(3). 37–46. 1 indexed citations

19.

Carpenter, J., et al.. (1975). Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).. PubMed. 58(5 Pt 1). 753–4. 6 indexed citations

20.

Carpenter, J., et al.. (1964). Human Erythrocyte Catalase: Demonstration of Heterogeneity and Relationship to Erythrocyte Ageing in vivo. British Journal of Haematology. 10(4). 542–550. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact